2022

Analysis of Cancer Medicine Availability in Aotearoa by Te Aho o Te Kahu

While we acknowledge Te Aho o Te Kahu for publishing this report, it is merely telling us what we already know. Notable is the timing of this report which well follows the review of Pharmac (and prior to that the flawed health system review..). Till now Te Aho o Te Kahu hasn’t acknowledged the huge […]

Lung Foundation NZ acknowledges decision to fund durvalumab

Pharmac’s decision to fund immunotherapy treatment durvalumab (imfinzi) for stage 3 lung cancer is a small step forward. Lung Foundation New Zealand (LFNZ) acknowledges the leaders and clinical advisors at Pharmac and the key people at AstraZeneca for getting durvalumab (imfinzi) across the line. This funding decision also highlights extreme inequities with access to treatments […]

Respiratory Research Review Features Lung Cancer

Lung Foundation New Zealand (LFNZ) really values the collaboration our cause has with Research Review. We’re pleased to publish the latest issue of Respiratory Research Review which focuses on Lung Cancer. Respiratory_Research_Review_Issue_193_Lung_Cancer

New research to focus on inequity in lung cancer

While, Lung Foundation New Zealand (LFNZ) endorses the funding decision and we applaud the efforts of the researchers that dedicate their life to improving health policy, providing lung cancer patients access to more treatment options NOW, will prevent premature death and eliminate inequities.   https://www.rnz.co.nz/news/national/459893/new-research-fund-to-focus-on-inequity-in-lung-cancer-treatment-diagnosis